The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
about
Drug interactions--principles, examples and clinical consequencesGauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokineticsRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Renal drug transporters and their significance in drug-drug interactionsNuclear receptor response elements mediate induction of intestinal MDR1 by rifampinSimultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesSaint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposurePrediction of promiscuous p-glycoprotein inhibition using a novel machine learning schemeDevelopment of novel rifampicin-derived P-glycoprotein activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, using paraquat as substrateThe Interactions of P-Glycoprotein with Antimalarial Drugs, Including Substrate Affinity, Inhibition and RegulationEffect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers.Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Pharmacokinetic interactions of drugs with St John's wort.Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.Intestinal permeability of metformin using single-pass intestinal perfusion in rats.ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2.A novel method using confocal laser scanning microscopy for sensitive measurement of P-glycoprotein-mediated transport activity in Caco-2 cells.Vanadate trapping of nucleotide at the ATP-binding sites of human multidrug resistance P-glycoprotein exposes different residues to the drug-binding siteMacrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycinHow to manage individualized drug therapy: application of pharmacogenetic knowledge of drug metabolism and transport.Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.Overcoming drug resistance by regulating nuclear receptors.Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elementsStructure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.Polymorphisms in the ABC drug transporter gene MDR1.Drugs as P-glycoprotein substrates, inhibitors, and inducers.Sucralose, a synthetic organochlorine sweetener: overview of biological issuesVery important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)Predicting inductive drug-drug interactions.Implications of pharmacogenetics for individualizing drug treatment and for study design.Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
P2860
Q24599421-D8936A70-20F9-48C7-A5DA-1775B37E172FQ24656624-B460E0E6-30A4-4B92-A817-D7791480EE75Q25255438-8A9E313A-E2FC-4F74-AA86-412781E54BE7Q28071292-0D8F7552-F49A-4675-96F8-A4318CA636E2Q28211706-2757AB2C-7154-4A8B-AC2A-BCA97CD285A0Q28269209-75FBFD94-D415-4F37-9E2F-14F0D4C20EE8Q28366014-A3058ADF-B922-47D3-84C8-27A6EA42CDB2Q28481547-E90A0FF1-9CA3-4498-B390-F80C447AF69FQ28535627-C08033E5-19D7-45C4-BDDD-A74593D3D085Q28551177-8A5FEB1B-4272-4D8E-B5E8-27FA9B4193E3Q30478126-36B202DE-FC1C-4C45-9EC8-B396C2B780CAQ30571118-3B52091C-E93B-4E6E-ADCE-CB05B425E549Q31043972-B3B338DB-34DE-442D-BE3F-3C98C5E968A1Q33204911-AC256013-C152-433A-BB62-AEF5A6B3D7A2Q33423486-97EC82C4-F780-46B4-B915-7BF5D9BE3BADQ33805141-2F3B4A70-BA79-43AB-B472-B69459FCCC56Q33867468-6B6392DA-B1F0-484C-ABF1-659917266B0BQ33938893-A5C99D79-4232-4679-9DB4-58351E6DF0EBQ33947052-AF6C7B5B-F371-4298-AFDE-E5039E3F41DBQ34018799-F7B82C06-E863-4102-8078-CE941B044723Q34049823-E7E7B542-435A-473E-8078-03137955FCD6Q34093093-86E41CB3-ED72-498B-BBE3-7EDF199165F3Q34146529-9A60CEF1-CD08-4F04-BD73-026DE7B5590AQ34149022-74B609F0-587C-4310-B2E9-BAB52B440A05Q34171741-CE1F7238-CD94-4337-BEA5-C0063F919EE0Q34187283-DAD53940-CBF2-410B-AF96-0051D3E7C74CQ34190195-2FD2328A-3CD6-434D-8E15-0FE1AC33ABD2Q34303346-15BD91F8-1765-4D33-8306-D757A57CE9D2Q34349313-F1EC649E-40F7-4330-BFE5-8A7B5E47C840Q34349336-E4BD876C-43F7-47CC-B09B-88D15CBC0351Q34448305-CE7BF12F-EEA3-4F69-A345-465450CCBE86Q34547632-3F18F988-2233-4297-BE2E-D3F513F98367Q34568808-CD5B365C-5144-478E-A4ED-F631B78F4E89Q34576932-057645A1-16F5-4F55-B189-AC4359BAF1FAQ34627908-E60A71BF-AA5F-4331-841E-C3D43C9554D3Q34657381-92FEB80E-3847-45FD-93A8-2A9D004CDDE6Q34994901-60463B5A-6524-4364-BFAB-6EF045A1D103Q35073283-7BD6F88E-57BD-409B-955A-01097EED263DQ35102211-6175E465-A622-4575-8BDE-5423F80458A1Q35113118-9467941C-E544-454D-B515-610AEF713637
P2860
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
@en
type
label
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
@en
prefLabel
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
@en
P2093
P2860
P356
P1476
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
@en
P2093
H K Kroemer
H P Kreichgauer
M Eichelbaum
O von Richter
P2860
P304
P356
10.1172/JCI6663
P407
P577
1999-07-01T00:00:00Z